Dorzolamide and Timolol Ophthalmic

Jump to navigation Jump to search

Dorzolamide and Timolol Ophthalmic
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vignesh Ponnusamy, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Dorzolamide and Timolol Ophthalmic is a combination of carbonic anhydrase inhibitor and beta-adrenergic blocker that is FDA approved for the {{{indicationType}}} of open-angle glaucoma or ocular hypertension. Common adverse reactions include hypertension, taste sense altered, dizziness, headache, tremor, blepharitis, blurred vision, burning sensation in eye, conjunctival hyperemia, excessive tear production, itching of eye, pain in eye, punctate keratitis, bronchitis, nasal congestion, upper respiratory infection.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Open-Angle Glaucoma or Ocular Hypertension
  • Dosing Information
  • Dorzolamide HCI/Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. was slightly less than that seen with the concomitant administration of 0.5% Timolol b.i.d. and 2.0% Dorzolamide t.i.d.
  • The dose is one drop of Dorzolamide HCl /Timolol Maleate Ophthalmic Solution in the affected eye(s) two times daily.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dorzolamide and Timolol Ophthalmic in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dorzolamide and Timolol Ophthalmic in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Open-Angle Glaucoma or Ocular Hypertension
  • Dosing Information
  • Dorzolamide HCI/Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. was slightly less than that seen with the concomitant administration of 0.5% Timolol b.i.d. and 2.0% Dorzolamide t.i.d.
  • The safety and effectiveness of Dorzolamide HCl Ophthalmic Solution and Timolol Maleate Ophthalmic Solution have been established when administered individually in pediatric patients aged 2 years and older.
  • The dose is one drop of Dorzolamide HCl /Timolol Maleate Ophthalmic Solution in the affected eye(s) two times daily.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dorzolamide and Timolol Ophthalmic in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dorzolamide and Timolol Ophthalmic in pediatric patients.

Contraindications

Warnings

  • Systemic Exposure
  • Dorzolamide HCI/Timolol Maleate Ophthalmic Solution contains Dorzolamide, a sulfonamide, and Timolol Maleate, a beta-adrenergic blocking agent; and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides and/or systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of Timolol Maleate.
  • Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.
  • Cardiac Failure
  • Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.
  • In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, Dorzolamide HCl /Timolol Maleate Ophthalmic Solution should be discontinued.
  • Obstructive Pulmonary Disease
  • Major Surgery
  • The necessity or desirability of withdrawal of eta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures.
  • Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.
  • If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.
  • Diabetes Mellitus
  • Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.
  • Thyrotoxicosis
  • Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism.
  • Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm.

Precautions

  • General
  • Dorzolamide has not been studied in patients with severe renal impairment (CrCl <30 mL/min). Because Dorzolamide and its metabolite are excreted predominantly by the kidney, Dorzolamide HCl /Timolol Maleate Ophthalmic Solution is not recommended in such patients.
  • Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.
  • While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.
  • In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic administration of Dorzolamide HCl /Timolol Maleate Ophthalmic Solution. Many of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. If such reactions are observed, Dorzolamide HCl / Timolol Maleate Ophthalmic Solution should be discontinued and the patient evaluated before considering restarting the drug.
  • The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide HCl /Timolol Maleate Ophthalmic Solution has not been studied in patients with acute angle-closure glaucoma.
  • Choroidal detachment after filtration procedures has been reported with the administration of aqueous suppressant therapy (e.g., Timolol).
  • Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
  • There is an increased potential for developing corneal edema in patients with low endothelial cell counts. Precautions should be used when prescribing Dorzolamide HCl / Timolol Maleate Ophthalmic Solution to this group of patients.

Adverse Reactions

Clinical Trials Experience

  • Other adverse reactions that have been reported with the individual components are listed below:

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Dorzolamide and Timolol Ophthalmic in the drug label.

Drug Interactions

  • Carbonic anhydrase inhibitors
  • There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and Dorzolamide HCl /Timolol Maleate Ophthalmic Solution. The concomitant administration of Dorzolamide HCl /Timolol Maleate Ophthalmic Solution and oral carbonic anhydrase inhibitors is not recommended.
  • Acid-base disturbances
  • Although acid-base and electrolyte disturbances were not reported in the clinical trials with Dorzolamide HCl Ophthalmic Solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving Dorzolamide HCl /Timolol Maleate Ophthalmic Solution.
  • Beta-adrenergic blocking agents
  • Patients who are receiving a beta-adrenergic blocking agent orally and Dorzolamide HCl /Timolol Maleate Ophthalmic Solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.
  • Calcium antagonists
  • Caution should be used in the coadministration of beta-adrenergic blocking agents, such as Dorzolamide HCl /Timolol Maleate Ophthalmic Solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, coadministration should be avoided.
  • Catecholamine-depleting drugs
  • Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
  • Digitalis and calcium antagonists
  • The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
  • CYP2D6 inhibitors
  • Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and Timolol.
  • Clonidine
  • Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. There have been no reports of exacerbation of rebound hypertension with ophthalmic Timolol Maleate.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category C
  • Developmental toxicity studies with Dorzolamide Hydrochloride in rabbits at oral doses of ≥2.5 mg/kg/day (31 times the recommended human ophthalmic dose) revealed malformations of the vertebral bodies. These malformations occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased fetal weights. No treatment-related malformations were seen at 1.0 mg/kg/day (13 times the recommended human ophthalmic dose).
  • Teratogenicity studies with Timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.
  • There are no adequate and well-controlled studies in pregnant women. Dorzolamide HCl / Timolol Maleate Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dorzolamide and Timolol Ophthalmic in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dorzolamide and Timolol Ophthalmic during labor and delivery.

Nursing Mothers

  • It is not known whether Dorzolamide is excreted in human milk. Timolol Maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from Dorzolamide HCl /Timolol Maleate Ophthalmic Solution in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

  • The safety and effectiveness of Dorzolamide HCl Ophthalmic Solution and Timolol Maleate Ophthalmic Solution have been established when administered individually in pediatric patients aged 2 years and older. Use of these drug products in these children is supported by evidence from adequate and well-controlled studies in children and adults. Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Geriatic Use

  • No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Gender

There is no FDA guidance on the use of Dorzolamide and Timolol Ophthalmic with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dorzolamide and Timolol Ophthalmic with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dorzolamide and Timolol Ophthalmic in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dorzolamide and Timolol Ophthalmic in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dorzolamide and Timolol Ophthalmic in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dorzolamide and Timolol Ophthalmic in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Topical

Monitoring

There is limited information regarding Monitoring of Dorzolamide and Timolol Ophthalmic in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Dorzolamide and Timolol Ophthalmic in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • There are no human data available on overdosage with Dorzolamide HCl /Timolol Maleate Ophthalmic Solution.

Management

  • A study of patients with renal failure showed that Timolol did not dialyze readily.

Chronic Overdose

There is limited information regarding Chronic Overdose of Dorzolamide and Timolol Ophthalmic in the drug label.

Pharmacology

Dorzolamide and Timolol Ophthalmic
Combination of
Dorzolamide Carboanhydrase inhibitor
Timolol Beta blocker
Identifiers
CAS number ?
ATC code S01ED51
PubChem 56841571
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

[[Prescription drug|Template:Unicode-only]](US)

Routes eye drops

Mechanism of Action

  • Dorzolamide HCI/Timolol Maleate Ophthalmic Solution is comprised of two components: Dorzolamide Hydrochloride and Timolol Maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.
  • Dorzolamide Hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Timolol Maleate is a beta1 and beta2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents administered as Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. results in additional intraocular pressure reduction compared to either component administered alone, but the reduction is not as much as when Dorzolamide t.i.d. and Timolol b.i.d. are administered concomitantly.

Structure

  • Dorzolamide Hydrochloride USP is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4Hthieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide Hydrochloride USP is optically active. The specific rotation is:
  • [α] 25°C (C=1, water) = ~ -17°.
  • 405 nm
  • Its empirical formula is C10H16N2O4S3•HCl and its structural formula is:
This image is provided by the National Library of Medicine.
  • Dorzolamide Hydrochloride USP has a molecular weight of 360.91. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.
  • Timolol Maleate USP is described chemically as: (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol Maleate USP possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of Timolol Maleate USP is:
  • [α] 25°C in 1N HCl (C = 5) = –12.2° (–11.7° to –12.5°).
  • 405 nm
  • Its molecular formula is C13H24N4O3S•C4H4O4 and its structural formula is:
This image is provided by the National Library of Medicine.
  • Timolol Maleate USP has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol Maleate USP is stable at room temperature.
  • Dorzolamide HCl /Timolol Maleate Ophthalmic Solution is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution. The pH of the solution is approximately 5.65, and the osmolarity is 242-323 mOsM. Each mL of Dorzolamide HCl /Timolol Maleate contains 20 mg Dorzolamide (22.26 mg of Dorzolamide Hydrochloride) and 5 mg Timolol (6.83 mg Timolol Maleate). Inactive ingredients are Hydroxyethyl Cellulose, Mannitol, Sodium Citrate Dihydrate, Sodium Hydroxide, and Water for Injection.
  • Benzalkonium Chloride 0.0075% is added as a preservative.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dorzolamide and Timolol Ophthalmic in the drug label.

Pharmacokinetics

  • Dorzolamide Hydrochloride
  • When topically applied, Dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in RBCs and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of binding to CA-II. The parent drug forms a single N-desethyl metabolite, which inhibits CA-II less potently than the parent drug but also inhibits CA-I. The metabolite also accumulates in RBCs where it binds primarily to CA-I. Plasma concentrations of Dorzolamide and metabolite are generally below the assay limit of quantitation (15nM). Dorzolamide binds moderately to plasma proteins (approximately 33%).
  • Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine. After dosing is stopped, Dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.
  • To simulate the systemic exposure after long-term topical ocular administration, Dorzolamide was given orally to eight healthy subjects for up to 20 weeks. The oral dose of 2 mg b.i.d. closely approximates the amount of drug delivered by topical ocular administration of Dorzolamide 2% t.i.d. Steady state was reached within 8 weeks. The inhibition of CA-II and total carbonic anhydrase activities was below the degree of inhibition anticipated to be necessary for a pharmacological effect on renal function and respiration in healthy individuals.
  • Timolol Maleate
  • In a study of plasma drug concentrations in six subjects, the systemic exposure to Timolol was determined following twice daily topical administration of Timolol Maleate Ophthalmic Solution 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility
  • In a two-year study of Dorzolamide Hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder papillomas were seen in male rats in the highest dosage group of 20 mg/kg/day (250 times the recommended human ophthalmic dose). Papillomas were not seen in rats given oral doses equivalent to approximately 12 times the recommended human ophthalmic dose. No treatment-related tumors were seen in a 21-month study in female and male mice given oral doses up to 75 mg/kg/day (~900 times the recommended human ophthalmic dose).
  • The increased incidence of urinary bladder papillomas seen in the high-dose male rats is a class-effect of carbonic anhydrase inhibitors in rats. Rats are particularly prone to developing papillomas in response to foreign bodies, compounds causing crystalluria, and diverse sodium salts.
  • No changes in bladder urothelium were seen in dogs given oral Dorzolamide Hydrochloride for one year at 2 mg/kg/day (25 times the recommended human ophthalmic dose) or monkeys dosed topically to the eye at 0.4 mg/kg/day (~5 times the recommended human ophthalmic dose) for one year.
  • In a two-year study of Timolol Maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.
  • In a lifetime oral study of Timolol Maleate in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine polyps and mammary adenocarcinomas in female mice at 500 mg/kg/day, (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.
  • The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral Timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of Timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.
  • The following tests for mutagenic potential were negative for Dorzolamide: (1) in vivo (mouse) cytogenetic assay; (2) in vitro chromosomal aberration assay; (3) alkaline elution assay; (4) V-79 assay; and (5) Ames test.
  • Timolol Maleate was devoid of mutagenic potential when tested in vivo (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and in vitro in a neoplastic cell transformation assay (up to 100 μg/mL). In Ames tests the highest concentrations of Timolol employed, 5,000 or 10,000 μg/plate, were associated with statistically significant elevations of revertants observed with tester strain TA100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.
  • Reproduction and fertility studies in rats with either Timolol Maleate or Dorzolamide Hydrochloride demonstrated no adverse effect on male or female fertility at doses up to approximately 100 times the systemic exposure following the maximum recommended human ophthalmic dose.

Clinical Studies

  • Clinical studies of 3 to 15 months duration were conducted to compare the IOP-lowering effect over the course of the day of Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. (dosed morning and bedtime) to individually- and concomitantly administered 0.5% Timolol (b.i.d.) and 2.0% Dorzolamide (b.i.d. and t.i.d.). The IOP-lowering effect of Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. was greater (1-3 mmHg) than that of monotherapy with either 2.0% Dorzolamide t.i.d. or 0.5% Timolol b.i.d.
  • The IOP-lowering effect of Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. was approximately 1 mmHg less than that of concomitant therapy with 2.0% Dorzolamide t.i.d. and 0.5% Timolol b.i.d.
  • Open-label extensions of two studies were conducted for up to 12 months. During this period, the IOP lowering effect of Dorzolamide HCI/Timolol Maleate Ophthalmic Solution b.i.d. was consistent during the 12 month follow-up period.

How Supplied

  • Dorzolamide HCl /Timolol Maleate Ophthalmic Solution is a clear, colorless to nearly colorless, slightly viscous solution.
  • Dorzolamide HCl /Timolol Maleate Ophthalmic Solution is supplied in a white low-density polyethylene (LDPE) bottle with a white LDPE dropper tip and a blue polypropylene cap as follows:
  • 5 mL in a 7.5 mL bottle - NDC 24208-486-05
  • 10 mL in a 10 mL bottle - NDC 24208-486-10
  • Storage
  • Store Dorzolamide HCl /Timolol Maleate Ophthalmic Solution at 20°-25°C (68°-77°F). Protect from light.
  • DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.
  • KEEP OUT OF REACH OF CHILDREN.

Storage

There is limited information regarding Dorzolamide and Timolol Ophthalmic Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Dorzolamide and Timolol Ophthalmic |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Dorzolamide and Timolol Ophthalmic |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

  • Dorzolamide HCl /Timolol Maleate Ophthalmic Solution contains Dorzolamide (which is a sulfonamide) and, although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration including severe skin reactions. Patients should be advised that if serious or unusual reactions or signs of hypersensitivity occur, they should discontinue the use of the product.
  • Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and lid reactions, they should discontinue use and seek their physician's advice.
  • Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.
  • Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
  • Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.
  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.
  • Patients should be advised that Dorzolamide HCl /Timolol Maleate Ophthalmic Solution contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of Dorzolamide HCl /Timolol Maleate Ophthalmic Solution.
Instructions for Use
  • Please follow these instructions carefully when using Dorzolamide HCl /Timolol Maleate Ophthalmic Solution. Use Dorzolamide HCl /Timolol Maleate Ophthalmic Solution as prescribed by your doctor.
  • If you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after Dorzolamide HCl /Timolol Maleate Ophthalmic Solution.
  • Wash hands before each use.
  • To open the bottle, remove the shrink neck band and unscrew the cap by turning counter clockwise.
  • Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.
  • Invert the bottle, and instill drops as directed by your doctor.
  • Do not touch your eye or eyelid with the dropper tip.
  • Ophthalmic medications, if handled improperly, can become contaminated by common bacteria known to cause eye infections. serious damage to the eye and subsequent loss of vision may result from using contaminated ophthalmic medications. if you think your medication may be contaminated, or if you develop an eye infection, contact your doctor immediately concerning continued use of this bottle.
  • Repeat steps 4 & 5 with the other eye if instructed to do so by your doctor.
  • Replace cap on bottle and turn until closed.
  • WARNING: KEEP OUT OF REACH OF CHILDREN.
  • If you have any questions about the use of Dorzolamide HCl /Timolol Maleate Ophthalmic Solution, please consult your doctor.
This image is provided by the National Library of Medicine.

Precautions with Alcohol

  • Alcohol-Dorzolamide and Timolol Ophthalmic interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • DORZOLAMIDE HCL /TIMOLOL MALEATE®[1]

Look-Alike Drug Names

There is limited information regarding Dorzolamide and Timolol Ophthalmic Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "DORZOLAMIDE HCL /TIMOLOL MALEATE- dorzolamide hydrochloride and timolol maleate solution/ drops".


{{#subobject: 

 |Page Name=Dorzolamide and Timolol Ophthalmic
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Dorzolamide and Timolol Ophthalmic
 |Label Name=Dorzolamide and Timolol Ophthalmic04.png

}}


{{#subobject: 

 |Label Page=Dorzolamide and Timolol Ophthalmic
 |Label Name=Dorzolamide and Timolol Ophthalmic05.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Dorzolamide_and_Timolol_Ophthalmic&oldid=1135221"